A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Inclusion Criteria:

• Confirmed history of moderate-to-severe OSA

• Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening

• Have a BMI ≥27 kg/m2 at screening

• Have a stable body weight (<5% body weight change) for 90 days prior to screening

• Have a history of at least one self-reported unsuccessful dietary effort to reducebody weight

For YSA1 Participants:

• Are unable or unwilling to use PAP therapy

For YSA2 Participants:

• Have been on PAP therapy for at least three consecutive months prior to screeningand plan to continue PAP therapy during the study

Exclusion Criteria:

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis,or abdominoplasty allowed if performed >1 year before screening)

• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 monthsprior to screening)

• Any previous or planned surgery for sleep apnea or major ear, nose or throat surgerythat still may affect breathing at time of screening

• Have type 1 diabetes, type 2 diabetes, or any other type of diabetes

• Have had within 90 days prior to screening:

• acute myocardial infarction

• cerebrovascular accident (stroke)

• coronary artery revascularization

• unstable angina, or

• hospitalization due to congestive heart failure

• Have a history or diagnosis of New York Heart Association Functional ClassificationClass IV congestive heart failure

• Have taken medications or alternative remedies intended for weight loss within 90days of screening